Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Hologic, Inc.

MyoSure NL

We’re an innovative medical technology company whose purpose is to enable healthier lives everywhere, every day. While we discover and develop groundbreaking products and services that benefit everyone, we are especially passionate about those that advance women’s health and well-being. This allows us to be a company that prospers, grows and empowers women to experience healthier lives.

None of this would be possible without the talent, skills and aspirations of our employees. Their expertise and dedication to developing and sharing more robust, science-based certainty drives our increasingly global presence, as well as a pipeline that responds to the unmet health and wellness needs of women, families and communities.

What powers our growth across Breast & Skeletal Health, Diagnostic Solutions, and GYN Surgical Solutions is also what differentiates us: the exceptional and clinically proven ability of our products to detect, diagnose and treat illnesses and other health conditions earlier and better. This clinical superiority creates high expectations, which we fulfill by always challenging ourselves to improve health through better technology, education and market access. Our goal is to minimize doubt and maximize the confidence our customers and their patients have in their decisions and diagnoses.

We work toward this goal every day, always aware that in an increasingly complex and competitive global environment, we must continually earn the trust of our customers and their patients. By focusing on women’s health while still delivering health benefits to everyone, we are setting a new standard of excellence that is strengthened by purpose, driven by passion and brought to life by our promise of more certain early detection and better health outcomes.  
To view our community guidelines, visit: www.hologic.com/social-media

Ascent Venture Partners

Reminder! Join Dr. Soyini Hawkins tomorrow, December 13 at 8 p.m. ET / 5 p.m. PT for an Acessa Patient Selection webinar.
Register now: https://bit.ly/3Qd17N6 #Hologic #FibroidAwareness

Join us at ASLM in Cape Town, South Africa from 12-15 December.

Find us at Booth 2, to meet our experts and learn more about our multi-disease testing capabilities and how our extensive portfolio of assays help you meet your lab's growing needs.
Our molecular testing portfolio is designed to bring clinical confidence and workflow efficiency to labs and clinicians whilst guiding patient care and enabling early detection. 

Are you attending?

We are proud to be recognized for the third consecutive year as one of America’s Most Responsible Companies by Newsweek! As a purpose-driven organization championing the health of women, their families and their communities, our employees work every day to be a global force for good. #WhyHologic https://ow.ly/lQV550QgYnr

Meet Gianluca, who is part of our diagnostics team in Italy. He explains how working at Hologic comes with a feeling of connection and belonging with his colleagues thanks to their shared dedication to enabling healthier lives. #WhyHologic

Our dedication to the fight against HIV and AIDS goes back to the 1990s when the National Heart, Lung, and Blood Institute (NHLBI) approached us to develop a nucleic acid blood screening test for the detection of HIV. Today, our cutting-edge HIV detection technology can help patients even more: https://bit.ly/49tsgDf #HIVAwarenessMonth

Join us on Monday, December 11th at 10am ET for “Access Across America: A Year-End Reflection on Women’s Health Policy.” This webinar hosted by our Director of Government Affairs Mia Keeys, will feature a panel of leading women’s health and policy experts reflecting on the developments of the past year and discussing what’s in store for 2024, with a special focus on rural and underserved communities across the United States. Register here: https://bit.ly/49YEV0W

	Sep '14	Sep '15	Sep '16	Sep '17	Sep '18	Sep '19	Sep '20	Sep '21	Sep '22	Sep '23	Sep '24
revenue	2.53B -	2.71B 6.89%	2.83B 4.72%	3.06B 7.98%	3.22B 5.20%	3.37B 4.64%	3.78B 12.15%	5.63B 49.14%	4.86B 13.66%	4.03B 17.12%	4.03B 0.00%
cost of revenue	1.29B -	1.27B 1.00%	1.27B 0.23%	1.44B 13.27%	1.52B 5.80%	2.06B 35.37%	1.55B 24.78%	1.84B 18.57%	1.87B 1.57%	1.96B 5.01%	1.80B 7.98%
gross profit	1.25B -	1.43B 15.03%	1.56B 9.12%	1.62B 3.69%	1.70B 4.67%	1.31B 22.90%	2.23B 70.29%	3.80B 70.41%	3.00B 21.03%	2.07B 30.89%	2.23B 7.55%
selling and marketing expenses	331.70M -	363M 9.44%	415.10M 14.35%	498.60M 20.12%	544.60M 9.23%	564.90M 3.73%	484.60M 14.21%	561.20M 15.81%	630.30M 12.31%	595.20M 5.57%	585.40M 1.65%
general and administrative expenses	259.80M -	261M 0.46%	267.30M 2.41%	343.30M 28.43%	366.10M 6.64%	332.30M 9.23%	356M 7.13%	433.20M 21.69%	407.70M 5.89%	392.40M 3.75%	409.40M 4.33%
selling general and administrative expenses	591.50M -	624M 5.49%	682.40M 9.36%	841.90M 23.37%	910.70M 8.17%	897.20M 1.48%	840.60M 6.31%	994.40M 18.30%	1.04B 4.38%	987.60M 4.86%	994.80M 0.73%
research and development expenses	203.20M -	214.90M 5.76%	232.10M 8.00%	232.80M 0.30%	218.70M 6.06%	232.20M 6.17%	222.50M 4.18%	276.30M 24.18%	283.40M 2.57%	294.30M 3.85%	272.80M 7.31%
other expenses	-3.60M -	-11M 205.56%	26.60M 341.82%	12.90M 51.50%	7.60M 41.09%	52M 584.21%	39.70M 23.65%	42.20M 6.30%	45.20M 7.11%	-1.70M 103.76%	77.60M 4,664.71%
cost and expenses	2.19B -	2.22B 1.26%	2.27B 2.35%	2.58B 13.26%	2.71B 5.24%	3.24B 19.58%	2.65B 18.17%	3.15B 18.77%	3.23B 2.62%	3.27B 1.14%	3.15B 3.71%
operating expenses	908.50M -	949.10M 4.47%	1.00B 5.81%	1.14B 13.24%	1.19B 4.53%	1.18B 0.61%	1.10B 6.65%	1.31B 19.05%	1.37B 4.09%	1.31B 4.14%	1.35B 2.69%
interest expense	220.60M -	205.50M 6.84%	155.30M 24.43%	153.20M 1.35%	148.70M 2.94%	140.80M 5.31%	116.50M 17.26%	93.60M 19.66%	95.10M 1.60%	111.10M 16.82%	-122.10M 209.90%
ebitda	447.20M -	965.30M 115.85%	1.05B 8.96%	949.70M 9.71%	1.00B 5.53%	597.50M 40.38%	1.51B 153.41%	2.89B 90.60%	2.10B 27.07%	1.20B 42.81%	882.60M 26.68%
operating income	279.70M -	455.10M 62.71%	548.60M 20.54%	1.37B 149.76%	-237.90M 117.36%	134.40M 156.49%	1.10B 722.17%	2.48B 124.46%	1.64B 33.87%	668.40M 59.25%	882.60M 32.05%
depreciation and amortization	113.80M -	491.40M 331.81%	465.40M 5.29%	449.20M 3.48%	480.30M 6.92%	463.10M 3.58%	409.10M 11.66%	405.50M 0.88%	464.50M 14.55%	323.40M 30.38%
total other income expenses net	-68.30M -	-102.20M 49.63%	10.80M 110.57%	896.10M 8,197.22%	-784.20M 187.51%	-229.70M 70.71%	-103.10M 55.12%	-119.20M 15.62%	-52M 56.38%	-94.80M 82.31%	-17.50M 81.54%
income before tax	48.10M -	177.20M 268.40%	415.30M 134.37%	1.23B 196.29%	-418.60M 134.02%	-95.30M 77.23%	1.00B 1,151.31%	2.36B 135.66%	1.59B 32.73%	676.10M 57.43%	865.10M 27.95%
income tax expense	30.80M -	45.60M 48.05%	84.50M 85.31%	475M 462.13%	-307.30M 164.69%	-55.10M 82.07%	-108.60M 97.10%	491.40M 552.49%	286.20M 41.76%	220.10M 23.10%	75.60M 65.65%
net income	17.30M -	131.60M 660.69%	330.80M 151.37%	755.50M 128.39%	-111.30M 114.73%	-40.20M 63.88%	1.12B 2,874.13%	1.87B 67.82%	1.30B 30.43%	456M 64.98%	789.50M 73.14%
weighted average shs out	275.50M -	280.57M 1.84%	280.21M 0.13%	279.81M 0.14%	275.11M 1.68%	269.41M 2.07%	262.73M 2.48%	257.05M 2.16%	251.53M 2.15%	246.77M 1.89%	235.72M 4.48%
weighted average shs out dil	278.36M -	289.54M 4.02%	286.16M 1.17%	285.65M 0.18%	275.11M 3.69%	269.41M 2.07%	264.61M 1.78%	259.71M 1.85%	253.84M 2.26%	248.83M 1.98%	237.55M 4.53%
eps	0.06 -	0.47 683.33%	1.18 151.06%	2.70 128.81%	-0.40 114.81%	-0.15 62.50%	4.24 2,926.67%	7.28 71.70%	5.18 28.85%	1.85 64.29%	3.35 81.08%
epsdiluted	0.06 -	0.45 650.00%	1.16 157.78%	2.64 127.59%	-0.40 115.15%	-0.15 62.50%	4.21 2,906.67%	7.21 71.26%	5.13 28.85%	1.83 64.33%	3.32 81.42%

COM:HOLOGIC

Hologic

Last Close

80.49

07/11 21:00

Market Cap

17.68B

Beta: -

Volume Today

1.46M

Avg: -

Preview